The high-speed train now has a new builder onboarded for the project. Photo of the N700 courtesy of © JR Central

The Texas high-speed train that plans to zip between Houston and Dallas still has some obstacles to plow through, but the project now has a builder at least.

Texas Central, the developer of the Texas Bullet Train, has signed a contract with Salini Impregilo, an Italian construction company and one of the largest civil engineering contractors in the world, and its American subsidiary, Lane Construction.

"This agreement brings us one step closer to beginning construction of the civil infrastructure segments of the project," said Texas Central CEO Carlos F. Aguilar, in a release.

The train still can't move forward because it doesn't own all of the land necessary for the route.

But if/when it does get the land, Salini Impregilo will do the following:

  • supply the civil and infrastructure scope, including the design and construction of the viaduct and embankment sections along the entire route
  • install the track system
  • oversee alignment and construction of all buildings and services that will house maintenance and other rail system equipment

Salini-Lane had previously provided front-end engineering and design for the train's civil infrastructure, as well as an analysis of construction costs and schedule estimates.

"Salini-Lane's unmatched track record with rail infrastructure and, very specifically, its world-class high-speed rail expertise across the globe will be central to the completion of America's first end-to-end high-speed rail system," Aguilar says.

Salini's CEO Pietro Salini says in a statement that the company is both thrilled and honored to bring its large-scale railway expertise to the project.

Salini Impregilo is active in more than 50 countries on five continents, with experience building more than 4,000 miles of railway infrastructure around the world. It has built high-speed train projects in Europe and some iconic projects in the world, including the expansion of the Panama Canal.

Although the company has worked in the U.S. since the 1980s, it expanded its presence in 2016 when it merged with The Lane Construction Corporation, a U.S.-based company with almost 130 years of experience in infrastructure work.

The Texas train will be based on Central Japan Railway's Tokaido Shinkansen train system, which is considered the safest mass transportation system in the world.

The system has transported more than 10 billion passengers in 54-plus years, with no fatalities or injuries from operations, and has an impeccable on-time performance record.

It will debut a new train, the Shinkansen N700S, the sixth generation of this train, before the 2020 Olympics.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston femtech co. debuts new lactation and wellness pods

mom pod

Houston-based femtech company Work&, previously known as Work&Mother, has introduced new products in recent months aimed at supporting working mothers and the overall health of all employees.

The company's new Lactation Pod and Hybrid Pod serve as dual-use lactation and wellness spaces to meet employer demand, the company shared in a news release. The compact pods offer flexible design options that can serve permanent offices and nearly all commercial spaces.

They feature a fully compliant lactation station while also offering wellness functionalities that can support meditation, mental health, telehealth and prayer. In line with Work&'s other spaces, the pods utilize the Work& scheduling platform, which prioritizes lactation bookings to help employers comply with the PUMP Act.

“This isn’t about perks,” Jules Lairson, Work& co-founder and COO, said in the release. “It’s about meeting people where they are—with dignity and intentional design. That includes the mother returning to work, the employee managing anxiety, and everyone in between.”

According to the company, several Fortune 500 companies are already using the pods, and Work& has plans to grow the products' reach.

Earlier this year, Work& introduced its first employee wellness space at MetroNational’s Memorial City Plazas, representing Work&'s shift to offer an array of holistic health and wellness solutions for landlords and tenants.

The company, founded in 2017 by Lairson and CEO Abbey Donnell, was initially focused on outfitting commercial buildings with lactation accommodations for working parents. While Work& still offers these services through its Work&Mother branch, the addition of its Work&Wellbeing arm allowed the company to also address the broader wellness needs of all employees.

The company rebranded as Work& earlier this year.

Rice biotech studio secures investment from Modi Ventures, adds founder to board

fresh funding

RBL LLC, which supports commercialization for ventures formed at the Rice University Biotech Launch Pad, has secured an investment from Houston-based Modi Ventures.

Additionally, RBL announced that it has named Sahir Ali, founder and general partner of Modi Ventures, to its board of directors.

Modi Ventures invests in biotech companies that are working to advance diagnostics, engineered therapeutics and AI-driven drug discovery. The firm has $134 million under management after closing an oversubscribed round this summer.

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. William McKeon, president and CEO of the TMC, previously called the launch of RBL a “critical step forward” for Houston’s life sciences ecosystem.

“RBL is dedicated to building companies focused on pioneering and intelligent bioelectronic therapeutics,” Ali said in a LinkedIn post. “This partnership strengthens the Houston biotech ecosystem and accelerates the transition of groundbreaking lab discoveries into impactful therapies.”

Ali will join board members like managing partner Paul Wotton, Rice bioengineering professor Omid Veiseh, scientist and partner at KdT Ventures Rima Chakrabarti, Rice alum John Jaggers, CEO of Arbor Biotechnologies Devyn Smith, and veteran executive in the life sciences sector James Watson.

Ali has led transformative work and built companies across AI, cloud computing and precision medicine. Ali also serves on the board of directors of the Drug Information Association, which helps to collaborate in drug, device and diagnostics developments.

“This investment by Modi Ventures will be instrumental to RBL’s growth as it reinforces confidence in our venture creation model and accelerates our ability to develop successful biotech startups,” Wotton said in the announcement. "Sahir’s addition to the board will also amplify this collaboration with Modi. His strategic counsel and deep understanding of field-defining technologies will be invaluable as we continue to grow and deliver on our mission.”